Advertisement
Journal of Cardiac Failure Home
Advanced searchSave search
Clinical Trial| Volume 13, ISSUE 5, P340-345, June 2007

The Safety of Amiodarone in Patients With Heart Failure

DOI:https://doi.org/10.1016/j.cardfail.2007.02.009
The Safety of Amiodarone in Patients With Heart Failure
Previous ArticleIsosorbide Dinitrate and Hydralazine in a Fixed-Dose Combination Produces Further Regression of Left Ventricular Remodeling in a Well-Treated Black Population With Heart Failure: Results From A-HeFT
Next ArticleRestrictive Filling Pattern is a Powerful Predictor of Heart Failure Events Postacute Myocardial Infarction and in Established Heart Failure: A Literature-Based Meta-Analysis

      Abstract

      Background

      Uncertainty persists about the safety and efficacy of amiodarone for the management of heart failure.

      Methods and Results

      We randomized 3029 patients with chronic heart failure to receive carvedilol or metoprolol and followed patients for a median of 58 months. One hundred fifty-five of 1466 patients in New York Heart Association (NYHA) Class II and 209 of 1563 in Class III or IV received amiodarone at baseline. Persistence with amiodarone treatment was high and 66% received amiodarone after 4 years. During follow-up, 38.7% and 58.9% of patients receiving amiodarone in NYHA Classes II and III + IV died versus 26.2% and 43.3% not receiving amiodarone (P < .001). This difference was maintained in multivariable analysis (hazard ratio [HR] 1.5, 95% confidence interval [CI] 1.2–1.7, P < .001). The difference was explained by an increased risk of death due to circulatory failure (HR 2.4, CI 1.9–3.1, P < .001) in patients receiving amiodarone. Sudden death was not different (HR 1.07, CI 0.8–1.4, P = .7). The increased risk was similar across NYHA classes with HR of 1.60 (CI 1.2–2.1, P < .001) in NYHA Class II versus 1.58 (CI 1.3–1.9, P < .001) in Classes III + IV.

      Conclusions

      Treatment with amiodarone was associated with an increased risk of death from circulatory failure independent of functional class.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Cardiac Failure
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Fuster V.
        • Ryden L.E.
        • Cannom D.S.
        • Crijns H.J.
        • Curtis A.B.
        • Ellenbogen K.A.
        • et al.
        ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.
        Europace. 2006; 8: 651-745
        View in Article
        • Doval H.C.
        • Nul D.R.
        • Perrone S.V.
        • Bortman G.R.
        • Curiel R.
        • (GESICA) fGdEdlSelIeA
        Randomized trial of low dose amiodarone in severe congestive heart failure.
        Lancet. 1994; 344: 493-498
        View in Article
        • Singh S.N.
        • Fletcher R.D.
        • Fisher S.G.
        • Singh B.N.
        • Lewis H.D.
        • Deedwania P.C.
        • et al.
        Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure.
        N Engl J Med. 1995; 333 ([comments]): 77-82
        View in Article
        • Bardy G.H.
        • Lee K.L.
        • Mark D.B.
        • Poole J.E.
        • Packer D.L.
        • Boineau R.
        • et al.
        Amiodarone or an Implantable Cardioverter-Defibrillator for Congestive Heart Failure.
        N Engl J Med. 2005; 352: 225-237
        View in Article
        • Poole-Wilson P.A.
        • Swedberg K.
        • Cleland J.G.
        • Di Lenarda A.
        • Hanrath P.
        • Komajda M.
        • et al.
        Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.
        Lancet. 2003; 362: 7-13
        View in Article
        • Poole-Wilson P.A.
        • Cleland J.G.
        • Di Lenarda A.
        • Hanrath P.
        • Komajda M.
        • Metra M.
        • et al.
        Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET.
        Eur J Heart Fail. 2002; 4: 321-329
        View in Article
        • Torp-Pedersen C.
        • Poole-Wilson P.
        • Swedberg K.
        • Cleland J.
        • Di Lenarda A.
        • Hanrath P.
        • et al.
        Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure—COMET.
        Am Heart J. 2005; 149: 370-376
        View in Article
        • Julian D.G.
        • Camm A.J.
        • Frangin G.
        • Janse M.J.
        • Munoz A.
        • Schwartz P.J.
        • et al.
        Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators.
        Lancet. 1997; 349: 667-674
        View in Article
        • Cairns J.A.
        • Connolly S.J.
        • Roberts R.
        • Gent M.
        Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators.
        Lancet. 1997; 349: 675-682
        View in Article
        • Massie B.M.
        • Fisher S.G.
        • Radford M.
        • Deedwania P.C.
        • Singh B.N.
        • Fletcher R.D.
        • et al.
        Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. CHF-STAT Investigators.
        Circulation. 1996; 93: 2128-2134
        View in Article
        • Macdonald P.S.
        • Keogh A.M.
        • Aboyoun C.
        • Lund M.
        • Amor R.
        • McCaffrey D.
        Impact of concurrent amiodarone treatment on the tolerability and efficacy of carvedilol in patients with chronic heart failure.
        Heart. 1999; 82: 589-593
        View in Article
        • Boutitie F.
        • Boissel J.P.
        • Connolly S.J.
        • Camm A.J.
        • Cairns J.A.
        • Julian D.G.
        • et al.
        Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators.
        Circulation. 1999; 99: 2268-2275
        View in Article

      Article info

      Publication history

      Accepted: February 28, 2007
      Received in revised form: February 23, 2007
      Received: October 26, 2006
      Copenhagen, Denmark; Brescia, Italy; Nottingham, United Kingdom; Basel, Switzerland; Heidelberg, Germany; Paris, France; Kingston upon Hull, United Kingdom; Rhoon, Netherlands; Göteborg, Sweden; London, United Kingdom

      Identification

      DOI: https://doi.org/10.1016/j.cardfail.2007.02.009

      Copyright

      © 2007 Elsevier Inc. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX